Localized scleroderma, as the term denotes, is localized to the skin on the hands and face. It is characterized by slow progression and rarely transforms to the systemic type. Localized scleroderma is ...

Padua, Italy - Although juvenile localized scleroderma is typically thought of as a skin disease, Dr Francesco Zulian reports in the September 2005 issue of Arthritis & Rheumatism that 22.4% of ...

Fibrocell Science has submitted an Investigational New Drug Application (IND) with the FDA for a gene therapy candidate to treat moderate to severe localized scleroderma. Fibrocell Science has ...

Patients with 3 subtypes of juvenile localized scleroderma (linear, generalized, and mixed) in the active phase were referred to a single center in Italy. They were randomly assigned in a 2:1 (active ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Fibrocell Science announced in a press ...

Clinical enrollment for an open-label, single-arm Phase 1/2 trial of FCX-013 was initiated in August 2018. Fibrocell Science announced that the Food and Drug Administration (FDA) has granted Fast ...

Q: My daughter, who is 14-years-old, was diagnosed with localized scleroderma about three years ago, and I am finding out that not much is known on this disease. Could you tell be about it? Does it ...

The advertiser paid a fee to promote this sponsored article and may have influenced or authored the content. The views expressed in this article are those of the advertiser and do not necessarily ...

EXTON, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue ...

The Global Localized Scleroderma Market is expected to reach at a Significant CAGR during the forecast period 2024-2031. The Localized Scleroderma Market is driven by rising autoimmune disease ...

DelveInsight’s ‘Scleroderma Pipeline Insights’ report lays down a holistic coverage of the available therapies, Scleroderma pipeline therapies in different developmental phases of clinical trials, key ...